| A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia MD Cappellini, V Viprakasit, AT Taher, P Georgiev, KHM Kuo, T Coates, ... New England Journal of Medicine 382 (13), 1219-1231, 2020 | 263 | 2020 |
| Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study RF Grace, P Bianchi, EJ van Beers, SW Eber, B Glader, HM Yaish, ... Blood, The Journal of the American Society of Hematology 131 (20), 2183-2192, 2018 | 158 | 2018 |
| Safety and efficacy of mitapivat in pyruvate kinase deficiency RF Grace, C Rose, DM Layton, F Galactéros, W Barcellini, DH Morton, ... New England Journal of Medicine 381 (10), 933-944, 2019 | 125 | 2019 |
| Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux KHM Kuo, MJ Kovacs Thrombosis and haemostasis 93 (05), 999-1000, 2005 | 119 | 2005 |
| Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis AK Malinowski, N Shehata, R D’Souza, KHM Kuo, R Ward, PS Shah, ... Blood, The Journal of the American Society of Hematology 126 (21), 2424-2435, 2015 | 100 | 2015 |
| Fondaparinux: a potential new therapy for HIT KHM Kuo, MJ Kovacs Hematology 10 (4), 271-275, 2005 | 76 | 2005 |
| Eculizumab and beyond: the past, present, and future of complement therapeutics CJ Patriquin, KHM Kuo Transfusion medicine reviews 33 (4), 256-265, 2019 | 66 | 2019 |
| Genotype‐phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency P Bianchi, E Fermo, K Lezon‐Geyda, EJ van Beers, HD Morton, ... American journal of hematology 95 (5), 472-482, 2020 | 56 | 2020 |
| Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study EJ Van Beers, S Van Straaten, DH Morton, W Barcellini, SW Eber, ... haematologica 104 (2), e51, 2019 | 56 | 2019 |
| Impact of a transition program with navigator on loss to follow‐up, medication adherence, and appointment attendance in hemoglobinopathies B Allemang, K Allan, C Johnson, M Cheong, P Cheung, I Odame, R Ward, ... Pediatric Blood & Cancer 66 (8), e27781, 2019 | 50 | 2019 |
| A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β … KHM Kuo, M Mrkobrada Hemoglobin 38 (6), 409-421, 2014 | 50 | 2014 |
| A comparison of chronic manual and automated red blood cell exchange transfusion in sickle cell disease patients. KHM Kuo, R Ward, B Kaya, J Howard, P Telfer British journal of haematology 170 (3), 2015 | 48 | 2015 |
| Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre … KHM Kuo, DM Layton, A Lal, H Al-Samkari, J Bhatia, PA Kosinski, B Tong, ... The Lancet 400 (10351), 493-501, 2022 | 45 | 2022 |
| The variable manifestations of disease in pyruvate kinase deficiency and their management H Al-Samkari, EJ Van Beers, KHM Kuo, W Barcellini, P Bianchi, ... Haematologica 105 (9), 2229, 2020 | 40 | 2020 |
| A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia presenting with hyperleucocytosis KHM Kuo, JL Callum, T Panzarella, LM Jacks, J Brandwein, M Crump, ... British journal of haematology 168 (3), 384-394, 2015 | 39 | 2015 |
| Prospective evaluation of an R2* method for assessing liver iron concentration (LIC) against FerriScan: derivation of the calibration curve and characterization of the nature … KS Jhaveri, SAR Kannengiesser, R Ward, K Kuo, MS Sussman Journal of Magnetic Resonance Imaging 49 (5), 1467-1474, 2019 | 32 | 2019 |
| Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial A Glenthøj, EJ van Beers, H Al-Samkari, V Viprakasit, KHM Kuo, ... The Lancet Haematology 9 (10), e724-e732, 2022 | 27 | 2022 |
| The International Hemoglobinopathy Research Network (INHERENT): An international initiative to study the role of genetic modifiers in hemoglobinopathies P Kountouris, C Stephanou, NM Archer, F Bonifazi, V Giannuzzi, ... Blood 138 (Supplement 1), 948-948, 2021 | 25 | 2021 |
| Comorbidities and complications in adults with pyruvate kinase deficiency AN Boscoe, Y Yan, E Hedgeman, EJ van Beers, H Al‐Samkari, ... European journal of haematology 106 (4), 484-492, 2021 | 22 | 2021 |
| The BELIEVE trial: results of a phase 3, randomized, double-blind, placebo-controlled study of luspatercept in adult beta-thalassemia patients who require regular red blood … MD Cappellini, V Viprakasit, A Taher, P Georgiev, KHM Kuo, TD Coates, ... Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | 21 | 2018 |
